One-year analysis of the iStent trabecular microbypass in secondary XXXX .

@entity1 @entity1538 @entity726 @entity134 @entity4461 @entity5891 @entity551
PURPOSE: To evaluate the midterm efficacy and safety of the iStent(  ) @entity726 device in @entity1 with secondary @entity1538 . @entity1 AND METHODS: A prospective, nonrandomized, interventional case series involving 10 @entity1 with secondary @entity1538 (traumatic, @entity134 , pseudoexfoliative, and @entity1538 ) of recent onset who underwent ab interno implantation iStent. @entity1 were assessed following the procedure on days 1, 7, and 15 and months 1, 3, 6, and 12, and examinations included visual acuity, intraocular pressure (IOP) measurement using Goldmann tonometry, number of @entity726 medications, and complications. Wilcoxon rank-test for data with abnormal distribution was used for the analysis of IOP and @entity726 medications at baseline versus 3, 6, and 12 months following the procedure. RESULTS: The mean baseline IOP was 26.5    7.9 (range 18-40) mmHg, and significantly decreased in 10.4    9.2 mmHg at three months (P < 0.05), in 7.4    4.9 mmHg at six months (P < 0.05), and in 6.6    5.4 mmHg at 12 months (P < 0.05) following iStent implantation. The mean number of @entity551 medications at baseline was 2.9    0.7 (range 2-4). Statistically significant reductions in the number of medications of 1.1    1.1 were observed at three months (P < 0.05), 1.0    0.7 at six months (P < 0.05), and 1.1    0.6 at 12 months (P < 0.05). No significant changes in visual acuity were noted. The most common complications comprised mild @entity5891 in seven eyes and transient IOP >= 30 mmHg in three eyes on postoperative day 1. Obstruction of the lumen of the stent with a @entity4461 was seen in three eyes, and all instances resolved spontaneously. CONCLUSION: The iStent is a safe and effective treatment option in @entity1 with secondary @entity1538 , and reduces the topical treatment burden in one @entity551 medication.
